Immunovant
320 West 37th Street
New York
NY
10018
United States
Tel: 9145222605
40 articles about Immunovant
-
Immunovant Awarded U.S. Patent for IMVT-1402
3/12/2024
Immunovant, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,926,669 for IMVT-1402, the Company’s second-generation antibody targeting the neonatal fragment crystallizable receptor.
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
2/12/2024
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.
-
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Immunovant, Inc. today announced that Pete Salzmann, M.D., chief executive officer, will provide a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am ET.
-
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
12/20/2023
Immunovant, Inc. (Nasdaq: IMVT) today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates.
-
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
12/20/2023
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates.
-
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
11/28/2023
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults.
-
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
11/28/2023
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults.
-
Immunovant to Present at Upcoming November 2023 Investor Conferences
11/13/2023
Immunovant, Inc., a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, announced that Pete Salzmann, M.D., chief executive officer, will participate in fireside chats at the following investor conferences.
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
11/9/2023
Immunovant, Inc. reported corporate updates and financial results for its fiscal second quarter ended September 30, 2023.
-
Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares
10/2/2023
Immunovant, Inc. announced the closing of its previously announced underwritten public offering of 8,475,500 shares of its common stock at a price of $38.00 per share.
-
Immunovant Announces Pricing of $450 Million Common Stock Financing
9/28/2023
Immunovant, Inc. announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately $450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions.
-
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
9/26/2023
Immunovant, Inc. announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in IgG in initial data from a Phase 1 clinical trial in healthy adults, with no dose-related changes in serum albumin or LDL-C, bolstering IMVT-1402 as a potential best-in-class neonatal fragment crystallizable receptor inhibitor.
-
Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023
9/26/2023
Immunovant, Inc., a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023.
-
Shares were up over 60% in premarket trading on news that the company’s anti-FcRn antibody exhibited dose-dependent reductions in IgG levels, drivers of inflammation in many autoimmune diseases.
-
Immunovant Announces Proposed Offering of $300 Million of Common Stock
9/26/2023
Immunovant, Inc., a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, announced the commencement of a proposed underwritten public offering and concurrent private placement of an aggregate of $300,000,000 of shares of its common stock.
-
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
9/26/2023
Immunovant, Inc. announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in IgG in initial data from a Phase 1 clinical trial in healthy adults, with no dose-related changes in serum albumin or LDL-C, bolstering IMVT-1402 as a potential best-in-class neonatal fragment crystallizable receptor inhibitor.
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
8/10/2023
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal first quarter ended June 30, 2023.
-
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023
5/22/2023
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal fourth quarter and fiscal year ended March 31, 2023.
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
2/3/2023
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal third quarter ended December 31, 2022.
-
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
11/7/2022
Immunovant, Inc. today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day, taking place November 14th -15th , 2022.